Paratek Pharmaceuticals, Inc. 8-K 2009
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
June 18, 2009 (June 16, 2009)
Date of Report (date of earliest event reported)
TRANSCEPT PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)
1003 W. Cutting Blvd., Suite #110
Point Richmond, California 94804
(Address of principal executive offices)
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
On June 16, 2009, Transcept Pharmaceuticals, Inc., a Delaware corporation (the Sublessor), entered into a sublease agreement dated for reference purposes as of June 11, 2009 (the Sublease) with Bay Area Bioscience Association, a California corporation (the Sublessee), for office space consisting of 6,920 square feet (the Subleased Premises) of Sublessors 25,288 total leased square footage at 400 Oyster Point Boulevard, Suite 200, South San Francisco, California.
The term of the Sublease commences on July 1, 2009 and ends on October 31, 2012. Sublessee does not have the option of extending the term of the Sublease. Notwithstanding the foregoing, both Sublessors and Sublessees obligations under the Sublease are conditioned upon receipt by Sublessor from Kashiwa Fudosan America, Inc., a California corporation (the Master Lessor), of Master Lessors written consent to the Sublease.
The total base rent payable by Sublessee to Sublessor through the end of the term of the Sublease is approximately $367,000. Sublessee is also obligated under the Sublease to deposit with Sublessor a security deposit in the amount of $12,500, in cash or in the form of an irrevocable standby letter of credit.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.